The Childhood Gender-Transition Industry Cannot Be Placed Beyond Scrutiny

File folders labeled documentation, violations, regulations, policies, and compliance on a desk.

The childhood gender-transition industry can place minors on dangerous and experimental gender-transition drugs after only an online visit. Those drugs are used to interrupt normal puberty or change sex characteristics during years when a child’s body and judgment are still developing. The stakes demand a clear look at how providers make those decisions, what families are told, and what happens when children experience adverse effects.

That is why a recent Ninth Circuit decision matters. On August 14, the court reversed an order that had quashed a Justice Department subpoena directed to QueerDoc, a telehealth provider, and sent the case back to the lower court. The decision leaves the merits of the government’s investigation unresolved. It puts records about prescribing, billing, informed consent, industry communications, and patient safety back at the center of the case.

The Records Reach Every Part of the Business

The subpoena reaches personnel files; billing, coding, and insurance reimbursement; communications with drug manufacturers and pharmacies; sponsorships and contracts; and medical records showing the basis for prescriptions. It also seeks informed-consent documents, parental authorizations, disclosures about off-label use and risks, safety communications, and reports of adverse effects in minor patients. Those records would show how a child moves from an online inquiry to a diagnosis and a prescription, who gets paid along the way, what families are told, and what providers learn after the drugs are administered.

An Online Visit Can Lead to Powerful Drugs

The opinion describes a medical pathway that begins with a free 15-minute consultation on QueerDoc’s website. A prospective patient uploads records and consent forms, then meets by video with a licensed professional for an hour. That clinician may diagnose gender dysphoria and prescribe puberty blockers or cross-sex hormones. The opinion also notes that neither class of drug is FDA-approved to treat gender dysphoria and that every such use is off-label. Children can enter this medical pathway through a screen and emerge with prescriptions designed to interrupt normal puberty or alter sex characteristics.

Children Should Never Be an Experiment

Puberty is a normal and necessary stage of human development. Deliberately suppressing it or adding opposite-sex hormones places a child’s developing body on an artificial course. These are dangerous, experimental interventions with the potential to shape health and life far beyond adolescence. A child living through a difficult season cannot fully measure what that path may mean years later. Adults and institutions have a duty to protect children from being placed on it.

The Promise of “Completely Reversible” Matters

The Ninth Circuit opinion points to a statement on QueerDoc’s website describing puberty blockers as “completely reversible.” The Justice Department says it is investigating whether public claims about these drugs are false or misleading under federal law. For a parent or child, the word “completely” conveys certainty at the moment a life-changing medical decision is being made. The subpoena seeks communications about safety, records of adverse effects, and the disclosures given to families. The provider’s own files are where that sweeping claim meets the real experience of patients.

Amendment 3 Can Make Missouri’s Protections Permanent

Missouri’s SAFE Act already bars gender-transition surgeries for minors and restricts providers from prescribing or administering puberty blockers and cross-sex hormones for gender transition, subject to limited statutory exceptions. The drug protections are scheduled to expire on August 28, 2027.

Amendment 3 would place protections against gender-transition surgeries, cross-sex hormones, and puberty-blocking drugs for minors in the Missouri Constitution without an expiration date. It retains exceptions for specified medical conditions. By voting yes, Missourians can keep a temporary drug safeguard from disappearing next year and make Missouri’s protection of children lasting.

Link to story: https://cdn.ca9.uscourts.gov/datastore/opinions/2026/08/14/25-7384.pdf

https://apnews.com/article/subpoenas-trump-transgender-care-187b7bea5f839146cffc45f206e51403

https://www.revisor.mo.gov/main/OneSection.aspx?section=191.1720

https://documents.house.mo.gov/billtracking/bills251/hlrbillspdf/2454H.05T.pdf

Previous
Previous

DOJ Accuses Kansas City, Kansas Schools of Hiding Children’s Gender-Transition Plans From Parents

Next
Next

Sophie Cunningham Is Right: Women’s Sports Are for Women